Jpmorgan Chase & CO Atai Life Sciences N.V. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 16,851 shares of ATAI stock, worth $25,613. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,851
Previous 17,924 5.99%
Holding current value
$25,613
Previous $23,000 17.39%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
SELL
$1.16 - $1.64 $1,244 - $1,759
-1,073 Reduced 5.99%
16,851 $19,000
Q2 2024

Aug 12, 2024
SELL
$1.27 - $2.6 $23,815 - $48,755
-18,752 Reduced 51.13%
17,924 $23,000
Q1 2024

May 10, 2024
SELL
$1.5 - $2.19 $422,007 - $616,130
-281,338 Reduced 88.47%
36,676 $72,000
Q4 2023

Feb 12, 2024
BUY
$1.04 - $1.55 $185,260 - $276,109
178,135 Added 127.35%
318,014 $448,000
Q3 2023

Nov 14, 2023
BUY
$1.27 - $2.28 $62,958 - $113,028
49,574 Added 54.9%
139,879 $180,000
Q2 2023

Aug 11, 2023
BUY
$1.44 - $2.19 $119,845 - $182,264
83,226 Added 1175.67%
90,305 $155,000
Q1 2023

May 11, 2023
SELL
$1.17 - $2.7 $15,632 - $36,074
-13,361 Reduced 65.37%
7,079 $12,000
Q4 2022

Feb 13, 2023
BUY
$2.38 - $3.55 $20,579 - $30,696
8,647 Added 73.32%
20,440 $55,000
Q3 2022

Nov 14, 2022
BUY
$3.14 - $4.87 $10,556 - $16,372
3,362 Added 39.88%
11,793 $39,000
Q2 2022

Aug 11, 2022
SELL
$3.03 - $5.32 $33,502 - $58,823
-11,057 Reduced 56.74%
8,431 $31,000
Q1 2022

May 11, 2022
BUY
$4.66 - $7.66 $24,963 - $41,034
5,357 Added 37.91%
19,488 $99,000
Q4 2021

Feb 10, 2022
BUY
$6.82 - $17.8 $96,373 - $251,531
14,131 New
14,131 $108,000

Others Institutions Holding ATAI

# of Institutions
87
Shares Held
12.4M
Call Options Held
77.8K
Put Options Held
50.3K
View Full List

About ATAI Life Sciences N.V.

ATAI Quotes by TradingView
  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $252M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email